Supernus Pharmaceuticals (SUPN) shares fell over 20% in Wednesday's premarket activity after the company said overnight its phase 2b study of SPN-820 in adults with treatment-resistant depression "did not" demonstrate a statistically significant improvement on the primary endpoint.
There was no treatment difference between SPN-820 and placebo in the change from baseline to week 4 for the secondary endpoints, the company said late Tuesday.
The multi-center, double-blind trial examined the efficacy and safety of SPN-820 over four weeks of treatment and then a week of "blinded placebo-washout" in about 250 patients from roughly 40 clinical sites.
Price: 31.71, Change: -8.04, Percent Change: -20.23
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。